

INDEX

Entries followed by *f* indicate figures; *t* indicates tables.

- AAAAI (American Academy of Allergy, Asthma & Immunology), 259
AAE (Association of Asthma Educators), 261
AAFA (Asthma and Allergy Foundation of America), 261
AANMA (Allergy & Asthma Network Mothers of Asthmatics, Inc), 259
AAP (American Academy of Pediatrics), 259
AARC (American Association for Respiratory Care), 260
ACAAI (American College of Allergy, Asthma & Immunology), 260
Accessory muscle use, 54
Access to medical care, factors interfering with, 23*t*
ACCP (American College of Chest Physicians), 260
AccuNeb, 94*t*
Ace Aerosol Cloud Enhancer, 171, 179*f*
Acebutol (Sectral), 226*t*
Aciphex (rabeprazole), 237*t*, 238*f*, 240
ACQ (Asthma Control Questionnaire), 115
Action mechanisms
 of anti-IgE monoclonal antibodies, 72*t*
 of anti-IgE therapies, 186, 187*f*
 of antileukotriene, 72*t*
 of β -agonists, 72*t*
 on bronchodilators, 89-90, 92-93*t*, 94-96*t*
 of corticosteroids, 72*t*, 111, 114
 of cromolyn sodium, 72*t*
 of methylxanthine, 72*t*
 of nedocromil sodium, 72*t*
 of omalizumab, 187*f*
Action points, need for clinical studies in identifying, 64
Ad Council-EPA (No Attacks), 264
Add-on and combination therapies, 11, 90-91, 145-163
 inhaled corticosteroids
 anti-IgE antibodies and, 162
 leukotriene modifiers and, 159-161
 long-acting β -agonists and, 145-158
 administration, 146-149
 addition of long-acting β -agonists (LABA) vs increase in inhaled corticosteroids dose, 147-148
 addition of long-acting β -agonists (LABA) vs placebo, 146-147
 corticosteroids as first-line therapy, 149
 fixed-dose combinations, 149-158, 152*f*
 inhaled corticosteroids and long-acting β -agonists, inhaled theophylline and, 161
Adolescents. *See also* Youth
 managing asthma in, 81, 88
Adults
 asthma in, 11, 21
 classifying asthma severity in, 44-45*f*
 LAR (late asthmatic response) in, 28
 stepwise approach for managing asthma in, 78-80*f*
Advair and Advair Diskus, 145, 149, 150*t*
Adverse effects
 of anesthetics, 216
 of aspirin or NSAIDs, 225
 of inhaled corticosteroids, 116, 118-120
 of omalizumab, 193
 of sulfites, 229
Aeroallergens, 64-65
 exposure to, 64
 in vitro reactivity to perennial, 185
Aerobid, 112*t*
AeroChamber spacers, 171, 180*f*
Age
 asthma and, 18, 21
 in comparison of extrinsic and intrinsic asthma, 18*t*
 death rate for asthma and, 22
Airborne chemicals or dusts, 38*t*
Airflow obstruction, 23, 47
 devices for serial monitoring of, 64
 physical findings associated with, 54
Airway hyperreactivity, 53
Airway inflammation, 11, 23
 allergen-specific IgE molecules as cause of, 185
 characteristics of, 111, 114
 mucosal, 29
 role of, in pathogenesis, 27-35, 111
 variability in pattern of, 12
Airway reactivity, role of, in pathogenesis, 27-35
Airway responsiveness to (AHR), 24
ALA (American Lung Association), 260-261
Alanine aminotransferase (ALT), 137
Albuterol, 33, 89, 90, 92*t*, 94*t*, 97, 100, 101, 151, 160, 168*t*, 208, 209, 241, 252*t*
Albuterol + ipratropium, 168*t*
Albuterol sulfate, 94
Alginate acid (Gaviscon), 237*t*
Allergens
 animal, 38*t*, 65, 67
 cockroach, 65, 67
 indoor, 64-65
 inhalant, 67
 outdoor, 64-65, 67
Allergen-specific immunoglobulin (IgE) antibodies, 185
Allergic asthma, 122
Allergic bronchopulmonary aspergillosis (ABPA), 224*t*, 242-243
 diagnostic features of, 243*t*
Allergic granulomatosis with angiitis, 242
Allergic occupational asthma, 244-245
Allergic rhinitis, 52
Allergic sensitization, 24, 64, 244
Allergy & Asthma Network Mothers of Asthmatics, Inc (AANMA), 259

Alternative therapies, 199-204
 cyclosporine, 204
 glucocorticoid-resistant asthma, 199-200
 gold, 202-203
 methotrexate, 200-202
 troleandomycin, 203
 Alupent, 95*t*
 Alveolar ventilation, 58
 Alvesco (HFA-MDI), 116
 American Academy of Allergy, Asthma & Immunology (AAAAI), 259
 American Academy of Pediatrics (AAP), 259
 American Association for Respiratory Care (AARC), 260
 American College of Allergy, Asthma & Immunology (ACAAI), 260
 American College of Chest Physicians (ACCP), 260
 American Lung Association (ALA), 260-261
 American Thoracic Society (ATS), 261
 criteria for airflow obstruction, 47
 Aminophylline, 104, 105*t*, 254
 Anaphylaxis, 193
 Anesthetics, 218
 Angiotensin-converting enzyme (ACE) inhibitors, 226-227*t*
 as cause of drug-induced asthma, 223
 in drug-induced bronchospasm or cough, 231-233
 Angiotensin II receptor blockers (ARBs), 232
 Animal allergens, 38*t*, 65, 67
 Animal models of asthma, 27
 Antacids, 237*t*
 Anticholinergics, 106, 107*t*
 combination of β -aerosols with, 210
 Antigen-specific immunoglobulin E (IgE) antibodies, 185
 Anti-IgE therapies, 185-196
 action mechanisms of, 72*t*, 186, 187*f*
 clinical studies, 186, 188, 189*t*, 190
 inhaled corticosteroids and, 162
 omalizumab
 action mechanisms of, 187*f*
 current clinical role of, 194, 196
 dosing of, 193-194, 195*t*
 safety of, 192-193
 Anti-inflammatory agents, 11, 13, 22, 71, 111-126, 227*t*
 corticosteroids, 111-114, 112-113*t*
 action mechanisms of, 111, 114
 cromoglycates, 120-121*t*, 122-125
 cromolyn sodium, 120, 121*t*, 122-123
 nedocromil sodium, 121*t*, 123-125
 inhaled corticosteroids, 114-116, 118-120
 adverse effects of, 116, 118-120
 undertreatment with, 11
 Antileukotrienes, 13, 32, 140
 action mechanisms of, 72*t*
 clinical properties of, 139*t*
 comparison of, 133*t*
 Antireflux medications, 237*t*
 AQLQ (Asthma Quality of Life Questionnaire), 191-192
 AQLQS (Asthma Quality of Life with Standardized Activities Questionnaire), 241
 Arachidonic acid
 cyclooxygenation of, 32
 lipoxygenation of, 32, 131
 Arg16 Arg variant, 33
 Arterial blood gas abnormalities, 58, 58*t*
 Asmanex Twisthaler, 113*t*, 116, 175*f*
 Aspergilloma, 243
 Aspergillus-related respiratory diseases, 242-243
 Aspirin (acetylsalicylic acid)
 as cause of drug-induced asthma, 224-225, 227-228
 cross-reaction of, in aspirin-sensitive asthma, 226-227*t*
 in drug-induced bronchospasm or cough, 224-225, 227-228
 sensitivity to, 65, 67
 Aspirin (acetylsalicylic acid)-induced asthma, 134
 Aspirin (acetylsalicylic acid)-sensitive asthma, 141, 227-228
 Assessment and monitoring, 12-13. *See also* Clinical evaluation and assessment of severity
 Association of Asthma Educators (AAE), 261
 Astemizole, 252*t*
 Asthma, 11-13
 allergic occupational, 244-245
 aspirin (acetylsalicylic acid)-induced, 134
 aspirin (acetylsalicylic acid)-sensitive, 141, 227-228
 bronchial, 11
 cardinal symptoms of, 37
 comparison of extrinsic and intrinsic, 18, 18*t*
 control of factors contributing to severity of, 64-65, 66*t*, 67
 cough-equivalent, 37
 defined, 15
 drug-induced, 224*t*, 226-227*t*, 226-233
 exercise-induced, 37, 91, 134, 141
 extrinsic, 18, 18*t*
 factitious, 53-54
 features of, 17*t*
 gastroesophageal reflux disease (GERD)-associated, 237-238, 239*f*
 glucocorticoid-resistant, 199-200
 goals of therapy for control of, 73
 home management of acute exacerbations of, 73, 81, 82-83*f*
 hospitalization rate in, 21
 intrinsic, 18, 18*t*
 key developments in field of, 11-12
 methotrexate for, 200-202
 nocturnal, 29, 91, 104
 nonallergic occupational, 244-245
 occupational, 244-245, 246-248*t*
 as outpatient disease, 13
 overlap between chronic obstructive airflow disorders and, 15, 16*f*

- Asthma (*continued*)
- pathogenesis of, 11
 - peak expiratory flow (PEF) monitoring as adjunct to education, 63
 - perioperative management of, 250, 253-254
 - point prevalence of, 24
 - prednisone-dependent, 201
 - recent trends in epidemiology of, 21-22
 - representative flow-volume loops, 49*f*
 - steroid-dependent, 199, 200, 202, 203, 204
- Asthma Action America, 261-262
- Asthma action plans, 13
- Asthma and Allergy Foundation of America (AAFA), 261
- Asthma Control Questionnaire (ACQ), 115
- Asthma inflammatory cascade, 30, 32-33
- proposed mechanism in, 31*f*
- Asthma mimics, 39*t*
- Asthma Quality of Life Questionnaire (AQLQ), 191-192
- Asthma Quality of Life with Standardized Activities Questionnaire (AQLQS), 241
- Asthma-related deaths, risk factors for, 22, 23*t*
- Asthma Society of Canada, 262
- Asthma syndrome, 15
- defining features of, 16*t*
- Asthma therapy
- general goals of, 61, 61*t*
 - key components of, 61, 62*t*
- Atenolol (Tenoretic, Tenormin), 226*t*, 230
- Athletes, vocal cord dysfunction in, 53-54
- Atopic disease, 12
- Atopy, 18
- in comparison of extrinsic and intrinsic asthma, 18*t*
- Atropine, 251*t*
- Atrovent, 107*t*
- ATS (American Thoracic Society), 261
- criteria for airflow obstruction, 47
- Auranofin, 202-203
- Azmacort, 113*t*
- β_2 -AR, 34
- Barbiturates, 254
- Barrett's esophagus, 236
- Basement membrane thickening, 29
- Beclomethasone, 117*t*, 188, 169*t*, 190
- Beclomethasone dipropionate, 252*t*
- Benazepril (Lotensin), 227*t*
- Benzalkonium chloride as cause in paradoxical bronchospasm, 99
- β -adrenergic blocking agents
- as cause of drug-induced asthma, 223
 - implication of, in drug-induced bronchospasm or cough, 227*t*, 230-231
- β -aerosols, combination of, with anticholinergics, 210
- β -agonists, 28. *See also* Bronchodilators
- action mechanisms of, 72*t*
 - administration of, 208
 - clinical response to, 33
 - controversy over, 11, 99-104
 - long-acting, 90, 91, 97-98, 103, 140, 145-146
 - overreliance on inhaled, 11, 22, 23*t*
 - role of, in asthma management, 90-91
- Betaxolol (Kerlone, Betoptic), 226*t*, 227*t*
- Bethanechol (Urecholine), 237*t*
- Biologic therapies, 12
- Biphasic decline in respiratory function, 27-28, 28*f*
- Bisoprolol (Zebeta, Ziac), 226*t*
- Bisulfite, 228
- Bitolterol, 92*t*
- Blacks
- asthma hospitalization rate for, 21
 - asthma in, 102
- Bradykinin, 231, 232
- Breathing, recurrent difficulty in, 38*t*
- Breath powered, dry-powder metered-dose inhaler (MDI), advantages and disadvantages of, 170
- Brethine, 96*t*
- Brompheniramine, 251*t*, 252*t*
- Bronchial asthma, 11
- conditions complicating, 224, 224*t*
 - gastroesophageal reflux disease (GERD) and, 233
- Bronchial hyperreactivity, 27, 52-53
- increase in, 99
- Bronchial hyperresponsiveness, 27
- Bronchial reactivity, airway inflammation and, 27
- Bronchiolitis, absence of, 29
- Bronchitis, chronic, 15, 16*t*
- Bronchoalveolar lavage, 218
- Bronchoconstriction, 32
- Bronchodilators, 71, 89-106
- action mechanisms and pharmacology of, 89-90, 92-93*t*, 94-96*t*
 - β -agonists
 - administration of, 208
 - clinical response to, 33
 - controversy over, 99-104
 - formoterol, 98
 - long-acting, 91, 97-98
 - role of, in asthma management, 90-91
 - salmeterol, 97-98
 - classes of, 89
 - inhaled devices for, 168*t*
 - in management of status asthmaticus, 208-210
 - sympathomimetics
 - generic and trade names, 94-96*t*
 - pharmacologic effects and pharmacokinetic properties of, 92*t*
 - theophylline, 104, 105*t*, 106, 106*t*

Bronchospasms. *See also* Drug-induced bronchospasm or cough drug-induced, 223-233, 224*t*, 226-227*t* paradoxical, 99

Budesonide, 156*f*, 169*t*, 252*t*

Budesonide DPI, 117*t*

Budesonide/formoterol, 116, 120, 154-155, 156*f*; 157-158, 169*t*

Budesonide plus formoterol, 156*f*

Candesartan (Atacand), 232

Captopril (Capoten), 226*t*

Carbachol, 227*t*

Cardiac disease, 224*t*
mimicking of asthma by, 223

Carvedilol (Coreg), 226*t*

Carvedilol (Coreg), 226*t*

Catecholamines, 89. *See also* Bronchodilators
examples of, 89

Centers for Disease Control and Prevention (CDC), 262

Chest tightness, 37
recurrent, 38*t*

Chest x-ray, 56-57

Children. *See also* Youth
asthma in, 11, 21, 122
classifying asthma severity and initiating treatment in, 40-43*f*
managing asthma in, 81, 88
stepwise approach for managing asthma in, 74-77*f*

Chlorofluorocarbon (CFC)-11 (primary solvent), 171, 183

Chlorofluorocarbon (CFC)-12 (primary propellant), 171

Chlorofluorocarbon (CFC)-propelled metered-dose inhaler (MDI)
advantages and disadvantages of, 170
environmental impact of, 171, 183

Chloroquine, 199

Chlorpheniramine, 251*t*, 252*t*

Cholesterol, 203

Chronic bronchitis, 15, 16*t*, 18
features of, 17*t*

Chronic eosinophilic pneumonia, 242

Chronic obstructive airflow disorders, asthma and, 15, 16*f*

Chronic obstructive pulmonary disease (COPD), 52
bronchospastic effects in, 230
typical features of, 17*t*
uses of, 230

Churg-Strauss syndrome, 119, 134, 242

Churg-Strauss vasculitis syndrome, 137

Ciclesonide, 116, 120, 169*t*

Cimetidine (Tagamet), 237*t*

Clinical evaluation and assessment of severity, 37-58
diagnosis, 37-53
classifying severity and initiating treatment in children 0 to 4 years of age, 40-41*f*
classifying severity in children 5 to 11 years of age, 42-43*f*

Clinical evaluation and assessment of severity, diagnosis (*continued*)
classifying severity in youths ≥ 12 years of age and adults, 44-45*f*
findings suggestive of status asthmaticus in emergency department, 46*t*
key indicators for, 38*t*
evaluation of severity, 54
factitious asthma (vocal cord dysfunction), 53-54
identifying high-risk patients and hospital admission criteria, 55-58
Clinical Practice Guidelines, 61*t*, 246-248*t*, 251*t*, 252*t*

Clinical studies. *See also* *In vitro* studies
of angiotensin-converting enzyme inhibitors, 232
of anti-IgE therapy, 186, 188, 189*t*, 190
of asthma during pregnancy, 249-250
on β -agonists, 209-210
on budesonide/formoterol, 158
Gaining Optimal Asthma Control (GOAL) study, 151
of GERD, 236, 241
in identifying cutoff or action points, 64
with leukotriene modifiers, 134, 135
of mechanical ventilation, 216
Salmeterol Multicenter Asthma Research Trial (SMART), 101-102
of troleanomycin, 203
on usefulness of PEF monitoring, 63
with zafirlukast, 136
with zileuton, 137-138

Closed-mouth method, 171

Cockroach allergens, 65, 67

Colchicine, 199

Combination therapies. *See* Add-on and combination therapies

Combivent, 107*t*

Comorbid illnesses
as complication with status asthmaticus, 207-208
management of bronchial asthma and, 223, 224*t*

Congestive heart failure, 52

Continuous nebulization, 208

Control, 12-13

Corticosteroids, 28, 111, 112-113*t*, 114. *See also* Anti-inflammatory agents
action mechanisms of, 72*t*, 111, 114
inhaled, 114-116, 118-120
inhaled devices for, 169*f*
in management of status asthmaticus, 210-212, 213*t*
metabolism of, 34
during pregnancy, 251*t*

Cough-equivalent asthma, 37, 51

Coughs, 37, 38*t*. *See also* Drug-induced bronchospasm or cough drug-induced, 223-233, 224*t*, 226-227*t*
exercise-related, 51
isolated, 37, 51
as side effect of ICSs, 116

Cromoglycates, 120-121*t*, 122-125
cromolyn sodium, 120, 121*t*, 122-123
nedocromil sodium, 121*t*, 123-125

- Cromolyn sodium, 28, 111, 120, 121*t*, 122-123, 162, 252*t*
 action mechanisms of, 72*t*
 comparison of nedocromil sodium and, 125
 trial of, 81
- Cutoff points, need for clinical studies in identifying, 64
- Cyclic adenosine monophosphate (cAMP), 89-90
- Cyclooxygenase (COX) inhibitors, 225, 227
- Cyclosporin A (CsA), 204
- Cyclosporine, 199, 204
 in glucocorticoid-resistant asthma, 200
- Cysteinyl leukotrienes, 131
- Dapsone, 199
- Death rate from asthma, 22, 100
- Dermatitis, 24
- Dermatophagoides farinae*, 65
- Dermatophagoides pteronyssinus*, 65
- Diagnosis, 37-53
 classifying severity and initiating treatment in children 0 to 4 years of age, 40-41*f*
 classifying severity in children 5 to 11 years of age, 42-43*f*
 classifying severity in youths ≥ 12 years of age and adults, 44-45*f*
 delayed, 11
 findings suggestive of status asthmaticus in emergency department, 46*t*
 in infants, 81
 key indicators for, 38*t*
- Diclofenac sodium (Voltaren), 226*t*
- Dihydrofolate reductase, 200
- Diminution of peak effect, 99
- Diphenhydramine, 251*t*
- Disease severity, 12-13
- Domperidone maleate (Motilum), 237*t*
- Dose-response effect, 115
- Drug-induced asthma, 224*t*, 226-227*t*, 226-233
 angiotensin-converting enzyme (ACE) inhibitors in, 231-233
 aspirin in, 224-225, 227-228
 β -blocking agents in, 230-231
 nonsteroidal anti-inflammatory drugs (NSAIDs) in, 224-225, 227-228
 sulfiting agents in, 228-229
 tartrazine in, 228
- Drug-induced bronchospasm or cough, 223-233, 224*t*, 226-227*t*
 angiotensin-converting enzyme inhibitors in, 231-233
 aspirin in, 224-225, 227-228
 β -blocking agents in, 230-231
 nonsteroidal anti-inflammatory drugs (NSAIDs) in, 224-225, 227-228
 sulfiting agents in, 228-229
 tartrazine in, 228
- Dry-powder inhalers (DPIs), 97, 114, 167, 174*t*, 183. *See also* Inhalation devices
 increased use of, 12
- D-Tubocurarine, 254
- Dyphylline, 105*t*
- Dysphonia, as side effect of ICSs, 116
- Dyspnea, 51, 53
 episodic, 37
- Early asthmatic response (EAR), 28, 30, 120, 123
- Early vs late asthma response, 27-30
- Echothiophate, 227*t*
- Edetate disodium as cause in paradoxical bronchospasm, 99
- Education. *See* Patient education
- Elixophyllin, 105*t*
- Emotional expression, 38*t*
- Emphysema, 15, 16*f*, 18
 features of, 17*t*
 representative flow-volume loops in, 49*f*
- Enalapril (Vasotec), 226*t*
- Endobronchial lesions, 57
- Environmental allergens, 12
- Environmental control, 13
- Eosinophils, 29, 30, 32
 infiltration of submucosa of, 29
- Ephedrine, 92*t*, 251*t*
- Epinephrine, 92*t*, 251*t*
- EpiPen, 95*t*
- Episodic dyspnea, 37
- Epithelial sloughing, 27, 29
- EPR-1 (1991) (Expert Panel Report), 12
- EPR-2 (1997) (Expert Panel Report 2) and EPR-Update 2002, 12, 61*t*, 62, 140, 210, 246-248*t*, 251*t*, 252*t*
- EPR-3 (2007) (Expert Panel Report), 12, 74-75*f*, 76-77*f*, 78-80*f*, 82-83*f*, 84-87*f*
- Eprosartan (Teveten), 232
- Esmolol (Brevibloc), 226*t*
- Esomeprazole (Nexium), 237*t*
- Ester-type local anesthetics, 254
- Ether, 216
- Ethylnorepinephrine, 92*t*
- European Respiratory Society (ERS), 262
- Evaluation. *See* Clinical evaluation and assessment of severity
- Exercise, 38*t*
- Exercise-induced asthma, 37, 122, 141
 formoterol for, 91
 leukotriene modifier for, 134
 salmeterol for, 91
- Exercise-induced bronchospasm, 51
- Exercise tolerance, 18
- Expert Panel Report (EPR-1) (1991). *See* EPR-1 (1991) (Expert Panel Report)
- Expert Panel Report (EPR-2) (1997). *See* EPR-2 (1997) (Expert Panel Report 2) and EPR-Update 2002
- Expert Panel Report (EPR-3) (2007). *See* EPR-3 (2007) (Expert Panel Report)

External triggers, in comparison of extrinsic and intrinsic asthma, 18*t*
Extrathoracic airway, 48
Extrinsic asthma, 18, 18*t*

Factitious asthma, 53-54
Family history, in comparison of extrinsic and intrinsic asthma, 18*t*
Famotidine (Pepcid), 237*t*
FDA (Food and Drug Administration)
 approval of leukotriene metabolism, 33
 approval of omalizumab, 194
 banning of use of sulfites, 229
 guidelines for asthma drugs during pregnancy, 250
 issuance of public health advisory on β -agonists, 99
 on products containing LABAs, 91, 97, 103, 145
Fenoterol, 100
Fibrosis, lack of, 29
Flovent HFA, 112*t*
Flovent Rotadisk, 112*t*
Flow-volume loops
 shape of, 47, 49*f*, 50*f*, 51
 for upper airway obstruction, 50*f*
Flunisolide, 112*t*, 117*t*, 169*t*, 252*t*
Fluticasone, 116, 117*t*, 149, 150-151, 154, 155*f*, 169*t*, 252*t*
Fluticasone propionate, 112*t*, 120
Food and Drug Administration, US (FDA). *See* FDA (Food and Drug Administration)
Foradil Aerolizer, 95*t*, 98
Forced expiratory volume in 1 second (FEV₁), 46, 55, 119-120
Forced vital capacity (FVC), 46-47, 48*f*
Formoterol, 89, 91, 93*t*, 95*t*, 102, 116, 119, 120, 126, 146, 147, 149, 154-155, 156*f*, 157-158, 160, 168*t*, 169*t*
Formoterol/budesonide (Symbicort), 98, 149
Formoterol fumarate, 95*t*
Formoterol single inhaler, 156*f*
Fosinopril (Monopril), 227*t*

Gaining Optimal Asthma Control (GOAL) study, 151
Gamma globulin, 199
Gas trapping, incomplete emptying of, 216
Gastroesophageal reflux disease (GERD), 67, 224*t*, 233-243
 bronchial asthma and, 233
 medical treatment, 236-237, 237*t*
 methodology issues, 234-236
 proposed approach to GERD-associated asthma, 237, 238-239*f*
 pulmonary infiltrates and bronchial asthma, 242-243
Gender, asthma and, 21
General Practice Research Database, United Kingdom, 235
GINA (Global Initiative for Asthma), 262-263
 guidelines for, 114-115
Global Initiative for Asthma (GINA). *See* GINA (Global Initiative for Asthma)

Glucocorticoid-resistant asthma, 199-200
Glucocorticoids for severe asthma, 211
Glucose, 203
Gly16Gly, 33
GM-CSF, 32
Gold, 202-203
Gold salts, 199
Granulation tissue, absence of, 29
Granulocyte-macrophage colony-stimulating factor (GM-CSF), 32

H₂-receptor antagonists, 237*t*
Halothane, 216, 254
Heart disease, coexistence of, with asthma, 223
Heart rate, 54
Heliox in management of acute asthma, 214
Helper T cells, 32
Herxheimer reaction, 27-28
High-risk patients, identifying, 55-58
Hispanics, asthma in, 22
Histamine, 122
 response to inhalation challenge of, 51, 52*f*
Histamine leukotrienes, 185
H⁺/K⁺-ATPase (proton pump) inhibitors, 237*t*
Holding chamber, 173*t*
Home management of acute exacerbations of asthma, algorithm for, 73, 81, 82-83*f*
Home peak expiratory flow (PEF) monitoring, 62
Homozygous pairing, 33
Hospital admission criteria, 55-58
 proposed spirometric, 211-212, 213*t*
Hospital-based care in management of asthma exacerbations, 84-87*f*
Hospital emergency department
 findings suggestive of status asthmaticus in, 46*t*
 in management of asthma exacerbations, 84-87*f*
Hospitalization for asthma, 21, 207-208
House dust mites, 38*t*, 65, 67
Human models of experimentally induced asthma, 27
Hydrocortone, 113*t*
Hydroxyzine, 251*t*
Hyperemesis gravidarum, 249
Hyperinflation, 56-57
Hypersensitivity pneumonitis, 243
Hypersensitivity-type response, 32
Hypertension as side effect of cyclosporin A (CsA), 204
Hypertrichosis as side effect of cyclosporin A (CsA), 204
Hypotension, 215-216

Ibuprofen (Advil, Motrin), 226*t*
Immunoglobulin G (IgG), 203
Impairment, 12-13
Indomethacin (Indocin), 226*t*

Indoor allergens, 64-65, 67
 Indoor molds, 65, 67
 Infants
 diagnosis of asthma in, 81
 managing asthma in, 81
 Influenza vaccinations for asthma patients, 65
 Inhalant allergens, 67
 Inhalational anesthetics, 218
 Inhalation devices, 97, 167-183, 168*t*, 169*t*. *See also* Dry-powder inhalers (DPIs); Metered-dose inhalers (MDIs)
 additional iterations in, 12
 advantages and disadvantages, 170-171, 172-174*t*, 175-182*f*, 183
 dry-powder inhalers, 183
 metered-dose, 168*t*, 169*t*, 170-171, 175*f*, 176*f*, 177*f*
 nebulizers, 170
 for bronchodilators, 168*t*
 for corticosteroids, 169*t*
 errors in use of, 167
 Inhaled corticosteroids (ICSs), 114-116, 118-120
 adverse effects, 116, 118-120
 anti-IgE antibodies and, 162
 estimated comparative daily doses for, 117*t*
 as first-line therapy, 90
 leukotriene modifiers and, 159-161
 long-acting β -agonists and, 145-158
 add-on administration, 146-149
 addition of long-acting β -agonists (LABA) vs increase in inhaled corticosteroids dose, 147-148
 addition of long-acting β -agonists (LABA) vs placebo, 146-147
 fixed-dose combinations, 149-158, 152*f*
 ICS/LABA vs ICS alone as first-line therapy, 149
 theophylline and, 161
 Inhaled corticosteroids-sparing effect, 148-149
 Inhaled steroids, clinical properties of, 139*t*
 InspirEase, 171, 181*f*
 Intal, 121*t*
 Intensive-care setting, mechanical ventilation in, 215-218, 217*t*
 Intensive-care unit (ICU), 211
 Interferon gamma (INF- γ), 32
 Interleukin-3 (IL-3), 32
 Interleukin-4 (IL-4), 32
 Interleukin-5 (IL-5), 32
 Intermittent, 13
 Intermittent bolus nebulization, 208
 Intrathoracic airway, 48
 Intravenous (IV) magnesium, rationale for use of, 214
 Intrinsic asthma, 18, 18*t*
 Intrinsic sympathomimetic activity, 230
 Invasive aspergillosis, 242
In vitro reactivity to perennial aeroallergens, 185

In vitro studies. *See also* Clinical studies
 on nedocromil sodium, 123-124
 on salmeterol, 97
In vitro testing, 65
 Ipratropium bromide, 107*t*, 168*t*, 231
 Irbesartan (Avapro), 232
 Isocyanates, exposure to, in LAR, 29
 Isoetharine, 89, 93*t*
 in management of status asthmaticus, 208
 Isoflurane, 254
 Isoproterenol, 89, 90, 93*t*, 251*t*

 Ketamine, 215-216
 Kininase II, 231

 Labetalol (Normodyne, Trandate), 226*t*
 Lansoprazole in treating gastroesophageal reflux disease (GERD), 237*t*, 241
 LAR (late asthmatic response), 28, 30, 90, 120, 123
 exposure to ozone and isocyanates in, 29
 Laryngoscopy, 53
 Late asthmatic response (LAR), 28, 30, 90, 120, 123
 Late vs early asthma response, 27-30
 Leukotriene B₄ (LTB₄), 32
 Leukotriene C₄ (LTC₄) synthase gene, 30, 32, 34
 Leukotriene cascade, 34
 Leukotriene D₄ (LTD₄), 32
 Leukotriene E₄ (LTE₄), 32
 Leukotriene metabolism, 33
 Leukotriene modifiers, 34, 131-141, 132*f*, 133*t*, 162
 clinical role for, 138-139*t*, 140-141
 comparison of clinical properties, 139*t*
 inhaled corticosteroids and, 159-161
 Montelukast (Singulair), 133*t*, 134-135
 Zafirlukast (Accolate), 136-137
 Zileuton (Zyflo), 137-138
 Leukotriene production, 34
 Levalbuterol, 168*t*
 Lipid mediators, 32
 5-Lipoxygenase (5-LO) promoter gene, 34
 Lisinopril (Prinivil, Zestril), 226*t*, 232
 5-LO inhibitor therapy, 34
 Long-acting β -agonists (LABA), 90, 91, 97-98, 103, 140, 145-146. *See also under* Inhaled corticosteroids (ICSs)
 addition of
 vs increase in inhaled corticosteroids dose, 147-148
 vs placebo, 146-147
 Losartan (Cozaar), 232
 LTC₄ synthase promoter gene (A-444C), 34
 Lufyllin, 105*t*
 The Lung Association, 263

- Lungs
 - assessment of function, 61
 - incomplete emptying of, 216
 - irreversible loss of function of, 23
- Lymphocytes, 30
- Lymphokines, 30
- Macrophages, 32
- Maintenance inhalational anesthetics, 254
- Management. *See* Pharmacologic management
- Maxair Autohaler, 95*t*
- Maxair Inhaler, 95*t*
- Mechanical ventilation
 - in management of status asthmaticus in intensive-care setting, 215-218, 217*t*
 - strategies and goals for, in status asthmaticus, 217*t*
- Mechanisms of action. *See* Action mechanisms
- Meclofenamate (Meclomen), 226*t*
- Medical history, items in, 39
- Medications. *See also specific*
 - action mechanisms of, 72*t*
- Medrol, 113*t*
- Mefenamic acid (Ponstel), 226*t*
- Men, asthma in, 21
- Menses, 38*t*
- Meperidine, 254
- Metabisulfite, 228
- Metaproterenol, 89, 90, 93*t*, 95*t*, 252*t*
 - in management of status asthmaticus, 208
- Metaproterenol sulfate, 95*t*
- Metered-dose inhalers (MDIs), 97, 99, 100, 114, 120, 167. *See also*
 - Bronchodilators; Corticosteroids; Inhalation devices
 - advantages and disadvantages of, 168*t*, 169*t*, 170-171, 175*f*, 176*f*, 177*f*
 - breath-powered, dry-powder, 170
 - chlorofluorocarbon (CFC)-propelled, 170, 171, 183
 - closed-mouth technique in using, 171
 - Maxair Autohaler, use of, 177*f*
 - open-mouth technique in using, 171, 176*f*
 - proper technique in using, 62
 - representative, 175*f*
- Metered-dose inhaler (MDI) spacer devices, 208
 - ACE Aerosol Cloud Enhancer, 179*f*
 - AeroChamber, 180*f*
 - InspirEase, 181*f*
 - OptiHaler, 182*f*
 - potency ration of nebulizer to, 209
 - schematic depiction of commonly used, 178*f*
- Methacholine, 122, 227*t*, 231
 - response to inhalation challenge of, 51, 52*f*
- Methotrexate, 199, 200-202
- Methylprednisolone, 113*t*, 210
- Methylxanthine
 - action mechanisms of, 72*t*
 - in management of acute asthma, 210
- Metoclopramide (Reglan), 237*t*
- Metoprolol (Lopressor), 226*t*, 230
- Microvascular leakage, 27
- Midazolam, 215
- Mild intermittent, 13
- Modifiers, leukotriene. *See* Leukotriene modifiers
- Moexipril (Univasc), 227*t*
- Molds, 38*t*, 64-65
- Mometasone, 116, 120, 169*t*, 252*t*
- Mometasone furoate, 113*t*, 116, 117*t*
- Montelukast (Singulair), 133*t*, 134-135, 140, 252*t*
- Morbidity, bronchial asthma as cause of, 11
- Morphine, 254
- Mucosa, inflammatory cellular infiltrate of, 27
- Mucosal edema, 30
- Mucus, hypersecretion of, 30
- Mucus plugging, 27
- Murine monoclonal antibody (mAb), 185
- Muscle relaxants, 254
- Mutations, data on, 34
- Myocardial infarction, 230
- Nadolol, 226*t*
- Naproxen (Naprosyn, Anaprox), 226*t*
- Nasal polyposis, 224*t*
- Nasal polyps, 65
- National Asthma Education and Prevention Program (NAEPP), 74-75*f*, 76-77*f*, 78-80*f*, 82-83*f*, 84-87*f*, 145, 263
 - guidelines for, 12, 90, 111, 138, 159, 161, 162, 208
 - EPR-1 (1991) (Expert Panel Report), 12
 - EPR-2 (1997) (Expert Panel Report 2) and EPR-Update 2002, 12, 73
 - EPR-3 (2007) (Expert Panel Report), 12, 40-41*f*, 42-43*f*, 44-45*f*, 56*f*, 57*f*, 61, 71, 73, 116
- National Center for Health Statistics, 21
- National Heart, Lung, and Blood Institute (NHLBI), 15, 40-41*f*, 42-43*f*, 44-45*f*, 74-75*f*, 76-77*f*, 78-80*f*, 82-83*f*, 84-87*f*, 263-264
- National Institute of Allergy and Infectious Diseases, 264
- National Jewish Medical and Research Center, 264
- Nebulization
 - continuous, 208
 - intermittent bolus, 208
- Nebulizers, 120, 167. *See also* Inhalation devices
 - advantages and disadvantages of, 170, 172*t*
 - potency ration of, to MDI with spacer, 209
- Nedocromil sodium, 28, 111, 121*t*, 123-125, 162, 252*t*
 - action mechanisms of, 72*t*
 - for angiotensin-converting enzyme (ACE) inhibitors cough, 233
 - comparison of cromolyn sodium and, 125
 - trial of, 81

Nephrotoxicity as side effect of cyclosporin A (CsA), 204
 Neurologic disturbances as side effect of cyclosporin A (CsA), 204
 Neuromuscular blockage, 217-218
 Neutrophils, 30, 32
 NHLABI (National Heart Lung and Blood Institute), 15, 40-41*f*, 42-43*f*,
 44-45*f*, 74-75*f*, 76-77*f*, 78-80*f*, 82-83*f*, 84-87*f*
 Nizatidine (Axid), 237*t*
 No Attacks (EPA-Ad Council), 264
 Nocturnal asthma, 29, 91, 104
 Nocturnal respiratory symptoms (NOC), 241-242
 Nonallergic factors, 67
 Nonallergic occupational asthma, 244-245
 Non-Hispanic blacks, asthma death in, 22
 Noninvasive, positive-pressure ventilation, in management of acute
 asthma, 214-215
 Nonpharmacologic therapy, 61-67
 control of factors contributing to asthma severity, 64-65, 66*t*, 67
 patient education, 61-63
 peak expiratory flow monitoring, 63-64
 Nonsmokers, attendance of asthma education programs by, 63
 Nonsteroidal anti-inflammatory drugs (NSAIDs)
 as cause of drug-induced asthma, 223, 224-225, 227-228
 cross-reaction of, in aspirin-sensitive asthma, 226-227*t*
 in drug-induced bronchospasm or cough, 224-225, 227-228
 sensitivity to, 65, 67
 Occupational asthma, 224*t*, 244-245, 246-248*t*
 allergic, 244-245
 nonallergic, 244-245
 Occupational exposures, 67
 Older adults, asthma management in, 88
 Olmesartan (Benicar), 232
 Omalizumab, 162, 185, 186. *See also* Anti-IgE therapies
 clinical studies of, 94, 186, 187*f*, 188, 189*f*, 190-192, 196
 current clinical role of, 194, 196
 dosing of, 193-194, 195*t*
 proposed action mechanisms of, 187*f*
 safety of, 192-193
 Omeprazole (Prilosec), 237*t*
 Open-mouth technique in using MDI, 171, 176*f*
 Ophthalmic agents, 227*t*
 Ophthalmic and systemic β -blockers, 67
 OptiHaler, 171, 182*f*
 Oral β -blockers, 226*t*
 Oral candidiasis, as side effect of ICSS, 116
 Organization-related resources, 259-265. *See also under* individual
 organizations
 Allergy & Asthma Network Mothers of Asthmatics, Inc. (AANMA), 259
 American Academy of Allergy, Asthma & Immunology (AAAAI), 259
 American Academy of Pediatrics (AAP), 259
 American Association for Respiratory Care (AARC), 260

Organization-related resources (*continued*)
 American College of Allergy, Asthma & Immunology (ACAAI), 260
 American College of Chest Physicians (ACCP), 260
 American Lung Association (ALA), 260-261
 American Thoracic Society (ATS), 261
 Association of Asthma Educators (AAE), 261
 Asthma Action America, 261-262
 Asthma and Allergy Foundation of America (AAFA), 261
 Asthma Society of Canada, 262
 Centers for Disease Control and Prevention (CDC), 262
 European Respiratory Society (ERS), 262
 Global Initiative for Asthma (GINA), 262-263
 The Lung Association, 263
 National Asthma Education and Prevention Program (NAEPP), 263
 National Heart, Lung, and Blood Institute, 263-264
 National Institute of Allergy and Infectious Diseases, 264
 National Jewish Medical and Research Center, 264
 No Attacks (EPA-Ad Council), 264
 Pulmonary Channel, 264
 Resource List for Asthma Education in the Schools, 265
 World Health Organization (WHO), 265
 Osteoporosis, 203
 Outdoor allergens, 64-65, 67
 Outdoor pollution and irritants, 67
 Outpatient asthma visits, 21
 Outpatient disease, asthma as, 13
 Ozone, exposure to, in LAR, 29
 Pantoprazole (Protonix), 237*t*
 Paradoxical bronchospasm, 99
 Parasympathomimetic drugs, 227*t*
 Parenchymal respiratory disorders, 52
 Pathogenesis, 27-35
 role of airway inflammation in, 111
 Pathogenesis of asthma, 11
 early vs late response, 27-30
 inflammatory cascade, 30, 31*f*, 32-33
 pharmacogenetics, 33-35
 Patient education
 access to nurse practitioner, 61
 on bronchodilators, 91
 need for aggressive, 13
 self-management skills in, 61
 written crisis plan in, 61, 62
 Patient errors in using inhalers, 167
 Peak expiratory flow (PEF) monitoring, 13, 22, 46, 55, 63-64
 home, 62
 predicted normal range for, by height for men and women, 57*f*
 Peak-flow meter, 38*t*
 in management occupational asthma, 245
 Penbutolol (Levitol), 226*t*

Perioperative management of asthma, 250, 253-254
 Pharmacogenetics, 11, 33-35
 Pharmacologic management, 71-88
 for asthma, 71, 72
 classification of, 71
 emergency department treatment, 81, 84-87*f*
 guidelines, 71, 73
 home treatment, 82-83*f*
 hospital-based care, 81, 84-87*f*
 stepwise approach to, 73, 74-80*f*
 Pharmacology of bronchodilators, 89-9, 92-93*t*, 94-96*t*
 Phenylephrine, 251*t*
 Phenylpropanolamine, 251*t*
 Pilocarpine, 227*t*
 Pindolol (Visken), 226*t*
 Pirbuterol, 93*t*, 168*t*
 Pirbuterol acetate, 95*t*
 Piroxicam (Feldene), 226*t*
 Placebo, addition of long-acting β -agonists (LABA) vs, 146-147
 Platelet-activating factor (PAF), 30, 32
 Pneumonia, 57
 Pneumothorax, 57
 Pollen, 38*t*, 64-65
 Polymorphisms in glucocorticoid receptor genes, 34-35
 Polymorphonuclear neutrophils (PMNs), 29
 Positive end-expiratory pressure (PEEP), incomplete emptying of, 216
 Postpartum hemorrhage, 249
 Pranlukast, 131, 133
 Predicted nomogram for peak expiratory flow by age, 56*f*
 Prednisone, 113*t*, 200, 201, 202, 252*t*
 Prednisone-dependent asthma, 113*t*, 201
 Pregnancy, asthma as threat in, 245, 249-250, 251*t*, 252*t*
 Prelone, 113*t*
 Pressurized MDI, 173*t*
 ProAir HFA, 94*t*
 Proinflammatory prostaglandins (PGD₂, PGF₂, TXB₂), 32
 Prokinetic agents, 237*t*
 Propofol, 215
 Propranolol (Inderal), 226*t*
 Prostaglandins, 32, 231
 Protoprium, 33, 89
 in management of status asthmaticus, 208
 Proventil, 94*t*
 Pulmicort Turbuhaler, 112*t*
 Pulmonary Channel, 264
 Pulmonary function testing, 22
 Pulmonary infiltrate with eosinophilia (PIE) syndromes, 242
 Pulmonary infiltrates and bronchial asthma, 224*t*, 242-243
 Pulsus paradoxus, 54

Quality of life, assessing changes in, 191-192
 Quinapril (Accupril), 227*t*
 Qvar, 112*t*

 Rabeprazole (Aciphex), 237*t*, 238*f*, 240
 Ramipril (Altace), 227*t*
 Ranitidine (Zantac), 237*t*
 Rebound bronchoconstriction, 99
 Receptor subsensitivity, 99
 Reduced duration of action, 99
 Remission, 23-24
 Remodeling, 11
 Residual volume (RV), 46
 Resorcinols, 89
 examples of, 89
 Respiratory function, biphasic decline in, 27-28, 28, 28*f*
 Respiratory rate, 54
 Responsiveness, 12
 Reverse-flow spacer, 173*t*
 Reversible airflow limitation, 38*t*
 Rhinitis, 67, 224*t*
 Risk factors for asthma-related deaths, 22, 23*t*

 Safety of omalizumab, 192-193
 Saligenins, 89
 examples of, 89
 Salmeterol, 89, 90, 91, 93*t*, 97-98, 149, 168*t*, 169, 252*t*
 side effects of, 97-98
 Salmeterol/fluticasone, 150-151, 152-153*f*, 154, 155*f*
 Salmeterol/fluticasone (Advair Diskus), 98
 Salmeterol Multicenter Asthma Research Trial (SMART), 101-102
 Salmeterol xinafoate, 96*t*, 97
 Seasonal variability in comparison of extrinsic and intrinsic asthma, 18*t*
 Semi-invasive aspergillosis, 243
 Sensitivity to aspirin, 67
 Serevent, 96*t*
 Serevent Diskus, 96*t*, 97
 Serial forced expiratory volume in 1 second (FEV₁), mean changes from
 baseline (before randomization) in, 152-153*f*
 Serologic testing, 229
 Severity. *See also* Clinical evaluation and assessment of severity
 classification of, 13
 evaluation of, 54
 Silent GERD, 235
 Single nucleotide polymorphisms (SNPs), 33
 Sinusitis, 67, 224*t*
 Skin testing, 65, 229
 Slow-reacting substance of anaphylaxis, 131
 Small-volume jet nebulizer, 172*t*
 SMART (Salmeterol Multicenter Asthma Research Trial), 101-102
 Smoke, 38*t*

Socioeconomic status, attendance at asthma education programs and, 63
 Sotalol (Betapace), 226*t*
 Spacer, 173*t*
 Spiriva Handihaler, 107*t*
 Spirometry, 47, 55
 normal, depicting volume-time curve and the flow-volume loop, 48*f*
 parameters for, 18
 proposed criteria for hospital admission, 211-212, 213*t*
 Status asthmaticus, 27, 104, 207-219
 complication of, with comorbid illness, 207-208
 defined, 207
 findings suggestive of, in emergency department, 46*t*
 hospitalization for, 207-208
 management
 bronchodilators, 208
 corticosteroids, 210-212, 213*t*
 mechanical ventilation, 215-218, 217*t*
 unconventional therapies, 212
 Step-down therapies, 120
 Stepwise approach to pharmacologic management, 73, 74-80*f*
 Sternocleidomastoid muscle retraction, 54
 Steroid-dependent asthma
 corticosteroids in, 115
 cyclosporine in, 204
 factors contributing to, 199
 gold in, 202
 methotrexate in, 200, 202
 need for oral steroids in, 199
 troleandomycin (TAO) in, 203
 Submucosa, inflammatory cellular infiltrate of, 27
 Substance of anaphylaxis (SRS-A), 32
 Substance P, 231, 232
 Succinylcholine, 254
 Sulfidopeptide leukotrienes, 227
 Sulfites, 229
 in drug-induced asthma, 223
 in drug-induced bronchospasm or cough, 226*t*, 228-229
 in paradoxical bronchospasm, 99
 Sulfur dioxide, bronchoconstriction on inhaling, 228-229
 Sulindac (Clinoril), 226*t*
 Sustained-release theophylline, 162
 Symbicort, 98
 Symbicort Turbohaler, 150*t*
 Sympathomimetic amine (dipivefrin), 227*t*
 Sympathomimetic bronchodilators
 generic and trade names, 94-96*t*
 pharmacologic effects and pharmacokinetic properties of, 92*t*
 Systemic steroids, beneficial effects of, 210

Tachyphylaxis, 33, 99
 Tartrazine
 as cause of drug-induced asthma, 223
 in drug-induced bronchospasm or cough, 228
 Telmisartan (Micardis), 232
 Terbutaline, 89, 93*t*, 252*t*
 Terbutaline sulfate, 96*t*
 Terfenadine, 252*t*
 Theo-24, 105*t*
 Theo-Dur, 105*t*
 Theophylline, 104, 105*t*, 106, 106*t*, 251*t*, 252*t*
 conditions affecting blood level, 106*t*
 inhaled corticosteroids and, 161
 in management of acute asthma, 210
 Therapies. *See also* Add-on and combination therapies; Alternative therapies; Anti-IgE therapies; Nonpharmacologic therapy
 biologic, 12
 step-down, 120
 Thromboxane (TXB₂), 32
 Tilade, 121*t*
 Timolol (Blocadren, Timolide, Timoptic), 226*t*, 227*t*
 Tiotropium, 168*t*
 Tiotropium bromide, 107*t*
 T lymphocytes, 32, 200
 Tobacco smoke, 67
 Tolerance, development of, 99
 Tolmetin (Tolectin), 226*t*
 Total lung capacity (TLC), 46
 Toxemia, 249
 Trandolapril (Mavik), 227*t*
 Triamcinolone, 169*t*, 252*t*
 Triamcinolone acetonide, 113*t*, 117*t*
 Tripeleminamine, 251*t*
 Tripolidine, 252*t*
 Troleandomycin (TAO), 199, 203
 Tumor necrosis factor alpha (TNF- α), 185
 Ultrasonic nebulizer, 172*t*-173
 Unconventional therapies in management of status asthmaticus, 12
 Uniphyll, 105*t*
 Upper airway obstruction (UAO), 47-48, 51
 flow-volume loops, 50*f*
 Upper respiratory tract infection, 52
 Vaccination, influenza, 65
 Valomotor rhinitis, 225
 Valsartan (Diovan), 232
 Ventolin HFA, 94*t*
 Viral infections, 12, 38*t*, 67
 Volmax, 94*t*
 VoSpire, 94*t*

Weather, changes in, 38*t*
Wheal-and-flare reaction, 18
Wheezing, 24, 37, 38*t*, 53
 recurrent, 38*t*
WHO (World Health Organization), 265
Women
 asthma death rate among, 22
 asthma in, 21
 attendance of asthma education programs by, 63
World Health Organization (WHO), 265

Xanthine derivatives and combinations, 105*t*

Youth. *See also* Adolescents; Children
 classifying asthma severity in, 44-45*f*
 stepwise approach for managing asthma in, 78-80*f*

Zafirlukast (Accolate), 133*t*, 134, 136-137, 252*t*
Zileuton (Zyflo), 133*t*, 134, 137-138, 252*t*